Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25821326 | 0.86 | HIF1A (0.37) | HIF1ACYP1A2CYP2D6ALOX15CTSB | |
| SCHEMBL12228922 | 0.83 | CYP2D6 (0.37) | HIF1ACYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL15765844 | 0.81 | HTT (0.39) | USP2TSHR | |
| SCHEMBL18199671 | 0.73 | — | — | |
| SCHEMBL26455588 | 0.73 | CYP2D6 (0.37) | CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL25001374 | 0.72 | OPRM1 (0.35) | HIF1ACYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL1753867 | 0.72 | TSHR (0.43) | HIF1ACYP1A2TSHR | |
| SCHEMBL12228917 | 0.72 | CYP1A2 (0.35) | CYP1A2CYP2D6ALOX15USP2CYP2C19 | |
| SCHEMBL12228921 | 0.72 | TSHR (0.33) | CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL22182595 | 0.72 | HIF1A (0.36) | HIF1ACYP1A2CYP2D6USP2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | HIF1A 3211/4885CYP1A2 3174/4885CYP2D6 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.